Serum osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

By Kananen K.   Volin L.   Laitinen K.   Ruutu T.   Välimäki M.  

Osteoporosis International, Vol. 17, Iss. 5, 2006-05 ,pp. : 724-730

Springer Publishing Company

Access to resources Recommend Favorite

Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein

By Sennels H. P.   Jacobsen S.   Jensen T.   Hansen M. S.   Østergaard M.   Nielsen H. J.   Sørensen S.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 67, Iss. 8, 2007-01 ,pp. : 821-835

Informa Healthcare

Access to resources Recommend Favorite

Preoperative Serum Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Predict Stabilization of Spontaneously Restored Sinus Rhythm in Persistent Atrial Fibrillation Patients after Mitral Valve Surgery

By  

Cardiology, Vol. 127, Iss. 3, 2014-01 ,pp. : 183-189

Karger

Access to resources Recommend Favorite

Implications of Measuring Soluble Receptor Activators of Nuclear Factor-κB Ligand and Osteoprotegerin in Bone Metabolism of Elderly Women

By  

Gerontology, Vol. 55, Iss. 3, 2009-01 ,pp. : 275-280

Karger

Access to resources Recommend Favorite

Increased Calcification in Osteoprotegerin-Deficient Smooth Muscle Cells: Dependence on Receptor Activator of NF-κB Ligand and Interleukin 6

By  

Journal of Vascular Research, Vol. 51, Iss. 2, 2014-03 ,pp. : 118-131

Karger

Access to resources Recommend Favorite